WHY ARE HUMAN-CELLS RESISTANT TO MALIGNANT-CELL TRANSFORMATION IN-VITRO

被引:48
|
作者
KUROKI, T
HUH, NH
机构
[1] Department of Cancer Cell Research, Institute of Medical Science, University of Tokyo, Tokyo, 108, 4-6-1 Shirokanedai, Minato-ku
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1993年 / 84卷 / 11期
关键词
HUMAN CELL; TRANSFORMATION; IMMORTALIZATION; CARCINOGEN; ONCOGENE;
D O I
10.1111/j.1349-7006.1993.tb02806.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transformation of human cells, both induced and spontaneous, is an extremely rare event, whereas rodent cells are relatively easily transformed when treated with a single carcinogenic agent. The present review addresses the question of why human cells are resistant to malignant transformation in vitro. To facilitate understanding of the problem, the process of transformation is divided operationally into two phases, i.e. phase I, immortalization; and phase II, malignant transformation. In human cells, one-phase transformation, i.e., the consecutive occurrence of phases I and II due to the action of a single carcinogenic agent, is observed only rarely. Once human cells are immortalized, however, malignant transformation by chemical carcinogens or oncogenes proceeds, suggesting that for human cells, phase I immortalization is a prerequisite for such transformation to take place. To date, about 20 papers have been published describing protocols for the two-phase transformation of a variety of human epithelial cells and fibroblasts. In most experiments, SV40, human papilloma viruses and their transforming genes are utilized for induction of phase I (immortalization) followed by the use of chemical carcinogens or activated oncogenes for induction of phase II (malignant transformation). Possible mechanisms that would render human cells refractory to transformation are discussed below.
引用
收藏
页码:1091 / 1100
页数:10
相关论文
共 50 条
  • [1] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON HEMATOPOIETIC AND NONHEMATOPOIETIC MALIGNANT-CELL GROWTH IN-VITRO
    ROSTI, V
    PEDRAZZOLI, P
    PONCHIO, L
    ZIBERA, C
    NOVELLA, A
    LUCOTTI, C
    DELLACUNA, GR
    CAZZOLA, M
    HAEMATOLOGICA, 1993, 78 (04) : 208 - 212
  • [2] MALIGNANT-CELL TRANSFORMATION AND ONCOGENES
    KISELEV, FL
    GENETIKA, 1985, 21 (06): : 885 - 895
  • [3] HUMAN-CELLS IN IN-VITRO PHARMACOTOXICOLOGY TESTING
    JEREMY, JY
    JOURNAL OF DRUG DEVELOPMENT, 1994, 6 (03): : 145 - 147
  • [4] MALIGNANT TRANSFORMATION OF CELLS CULTIVATED IN-VITRO
    RAVINA, A
    PRESSE MEDICALE, 1971, 79 (19): : 881 - &
  • [5] MALIGNANT-CELL LINES - WHY USE APUDOMA
    MOORE, GE
    NATURE, 1984, 311 (5985) : 417 - 417
  • [6] PHOSPHORYLATING PROTEINS AS EFFECTORS IN MALIGNANT-CELL TRANSFORMATION
    KURTH, R
    STEGMANN, J
    TANAKA, T
    LOWER, J
    FRANK, H
    ADVANCES IN CYCLIC NUCLEOTIDE RESEARCH, 1981, 14 : 443 - 462
  • [7] CYTOGENETIC EFFECTS OF THE ANTICHAGASIC BENZNIDAZOLE ON HUMAN-CELLS IN-VITRO
    SANTOS, SJ
    TAKAHASHI, CS
    NATARAJAN, AT
    MUTATION RESEARCH, 1994, 320 (04): : 305 - 314
  • [8] MALIGNANT TRANSFORMATION OF MAMMALIAN-CELLS IN CULTURE, INCLUDING HUMAN-CELLS
    MCCORMICK, JJ
    MAHER, VM
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 1989, 14 : 105 - 113
  • [9] PARTICIPATION OF DNA-SYNTHESIS TO MALIGNANT-CELL TRANSFORMATION
    WATANABE, M
    KODAMA, S
    NIKAIDO, O
    JOURNAL OF RADIATION RESEARCH, 1983, 24 (01) : 56 - 57
  • [10] ROLE OF POLYOMA T ANTIGENS IN MALIGNANT-CELL TRANSFORMATION
    ECKHART, W
    PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, 1983, 29 : 119 - 125